Mario E. Lacouture

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Igor Puzanov, Adi Diab, K. Abdallah et al. · Journal for ImmunoTherapy of Cancer · 2017 · 2K citations · Full text

Life Sciences, Immunology, Oncology +17

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2021 · 826 citations · Full text

Pharmacy, Immunology, Oncology +17

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer et al. · Journal of the National Comprehensive Cancer Network · 2019 · 560 citations · Full text

Medicine, Oncology, Oncology Nursing +17

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Eli L. Diamond, Benjamin H. Durham, Julien Haroche et al. · Cancer Discovery · 2015 · 533 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +10

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi et al. · Journal of Clinical Oncology · 2010 · 475 citations

Medicine, Oncology, Pharmacology +16